The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
Stay Connected. Manage Your Care.
Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you
whenever you need it. Give us a call at
650-498-3333 or
PHYSICIAN HELPLINE
Have a question? We're here to help! Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
David J. Maron
Cardiologist
Professional Education
- Residency: Stanford University Hospital -Clinical Excellence Research CenterCA
- Medical Education: Univ Of So Ca - Los Angeles (1981) CA
- Residency: UCLA Health SciencesCA
- Internship: UCLA Health SciencesCA
- Fellowship: Stanford University - Cardiovascular MedicineCA
- Board Certification: Cardiovascular Disease, American Board of Internal Medicine (1991)
- Board Certification: Internal Medicine, American Board of Internal Medicine
Publications
-
Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)
Bradley, S. M., Chan, P. S., Hartigan, P. M., Nallamothu, B. K., Weintraub, W. S., & Spertus, J. A. (2015). Validation of the Appropriate Use Criteria for Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (from the COURAGE Trial). AMERICAN JOURNAL OF CARDIOLOGY, 116(2), 167-173. -
Primary Prevention of Heart Failure in Older Adults.
Maron, D. J., & Hunt, S. A. (2015). Primary Prevention of Heart Failure in Older Adults. JACC. Heart failure, 3(7), 529-530. -
Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)".
Doran, B., Guo, Y., Xu, J., Weintraub, H., Mora, S., & Bangalore, S. (2015). Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". Circulation, 131(19). -
Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III).
Doran, B., Guo, Y., Xu, J., Weintraub, H., Mora, S., & Bangalore, S. (2014). Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III). Circulation, 130(7), 546-553.
-
Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs.
Maron, D. J., & Hlatky, M. A. (2014). Trial to Assess Chelation Therapy (TACT) and equipoise: When evidence conflicts with beliefs. American heart journal, 168(1), 4-5.
-
Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging
Shaw, L. J., Berman, D. S., Picard, M. H., Friedrich, M. G., Kwong, R. Y., & Douglas, P. S. (2014). Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear, Echocardiography, and Magnetic Resonance Imaging. JACC-CARDIOVASCULAR IMAGING, 7(6), 593-604.
-
As REGARDS treatment goal attainment compared with COURAGE: the perfect should not be the enemy of the good.
Maron, D. J., & Boden, W. E. (2014). As REGARDS treatment goal attainment compared with COURAGE: the perfect should not be the enemy of the good. Journal of the American College of Cardiology, 63(16), 1634-1635.
-
Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients A Post-Hoc Analysis From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
Acharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., & Weintraub, W. S. (2013). Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients A Post-Hoc Analysis From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 62(20), 1826-1833.
-
Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial
Spertus, J. A., Maron, D. J., Cohen, D. J., Kolm, P., Hartigan, P., & Mancini, G. Bj. (2013). Frequency, Predictors, and Consequences of Crossing Over to Revascularization Within 12 Months of Randomization to Optimal Medical Therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 6(4), 409-418.
-
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention
Shaw, L. J., Weintraub, W. S., Maron, D. J., Hartigan, P. M., Hachamovitch, R., & Berman, D. S. (2012). Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. AMERICAN HEART JOURNAL, 164(2), 243-250.
-
Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists
Maron, D. J., Stone, G. W., Berman, D. S., Mancini, G. Bj., Scott, T. A., & Spertus, J. A. (2011). Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web-based survey of cardiologists. AMERICAN HEART JOURNAL, 162(6), 1034-U124.
-
Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy Observations From the COURAGE Trial
Mancini, G. Bj., Hartigan, P. M., Bates, E. R., Sedlis, S. P., Maron, D. J., & Boden, W. E. (2011). Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy Observations From the COURAGE Trial. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 4(6), 545-552.
-
Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial
Maron, D. J., Boden, W. E., Spertus, J. A., Hartigan, P. M., Mancini, G. Bj., & O'Rourke, R. A. (2011). Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 58(2), 131-137.
-
Intensive Multifactorial Intervention for Stable Coronary Artery Disease Optimal Medical Therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial
Maron, D. J., Boden, W. E., O'Rourke, R. A., Hartigan, P. M., Calfas, K. J., & Teo, K. K. (2010). Intensive Multifactorial Intervention for Stable Coronary Artery Disease Optimal Medical Therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 55(13), 1348-1358.
-
Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial
Maron, D. J., Spertus, J. A., Mancini, G. Bj., Hartigan, P. M., Sedlis, S. P., & Boden, W. E. (2009). Impact of an Initial Strategy of Medical Therapy Without Percutaneous Coronary Intervention in High-Risk Patients From the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial. AMERICAN JOURNAL OF CARDIOLOGY, 104(8), 1055-1062.
-
Effect of PCI on quality of life in patients with stable coronary disease
Weintraub, W. S., Spertus, J. A., Kolm, P., Maron, D. J., Zhang, Z., & Boden, W. E. (2008). Effect of PCI on quality of life in patients with stable coronary disease. NEW ENGLAND JOURNAL OF MEDICINE, 359(7), 677-687.
-
Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden - Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy
Shaw, L. J., Berman, D. S., Maron, D. J., Mancini, J., Hayes, S. W., & Boden, W. E. (2008). Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden - Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. CIRCULATION, 117(10), 1283-1291.
-
Optimal medical therapy with or without PCI for stable coronary disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., & Mathien, J. (2007). Optimal medical therapy with or without PCI for stable coronary disease. NEW ENGLAND JOURNAL OF MEDICINE, 356(15), 1503-1516.
-
EFFECTS OF INTENSIVE MULTIPLE RISK FACTOR REDUCTION ON CORONARY ATHEROSCLEROSIS AND CLINICAL CARDIAC EVENTS IN MEN AND WOMEN WITH CORONARY-ARTERY DISEASE - THE STANFORD-CORONARY-RISK-INTERVENTION-PROJECT (SCRIP)
Haskell, W. L., Alderman, E. L., Fair, J. M., Maron, D. J., Mackey, S. F., & Farquhar, J. W. (1994). EFFECTS OF INTENSIVE MULTIPLE RISK FACTOR REDUCTION ON CORONARY ATHEROSCLEROSIS AND CLINICAL CARDIAC EVENTS IN MEN AND WOMEN WITH CORONARY-ARTERY DISEASE - THE STANFORD-CORONARY-RISK-INTERVENTION-PROJECT (SCRIP). CIRCULATION, 89(3), 975-990.
-
SATURATED FAT INTAKE AND INSULIN RESISTANCE IN MEN WITH CORONARY-ARTERY DISEASE
Maron, D. J., Fair, J. M., & Haskell, W. L. (1991). SATURATED FAT INTAKE AND INSULIN RESISTANCE IN MEN WITH CORONARY-ARTERY DISEASE. CIRCULATION, 84(5), 2020-2027.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Sep 2015
Fantastic. As retired Stanford faculty, I was surprised & pleased by QUANTITY and quality of care.
SHC Patient, Aug 2015
Very good experience.
SHC Patient, Aug 2015
Good.
SHC Patient, Jul 2015
Dr. Maron is a gift - great doctor!!
SHC Patient, Jun 2015
My doctor was very professional.
SHC Patient, May 2015
All excellent!
SHC Patient, Apr 2015
My experience with Dr. Maron was the best I have had with a doctor at Stanford.
SHC Patient, Feb 2015
Very, very professional!
SHC Patient, Jan 2015
Good.
SHC Patient, Dec 2014
Dr. Maron was fantastic. Explained his findings and clearly had reviewed my medical history. Made me feel at ease.
SHC Patient, Sep 2015
Fantastic. As retired Stanford faculty, I was surprised & pleased by QUANTITY and quality of care.
SHC Patient, Aug 2015
Very good experience.
SHC Patient, Aug 2015
Good.
SHC Patient, Jul 2015
Dr. Maron is a gift - great doctor!!
SHC Patient, Jun 2015
My doctor was very professional.
SHC Patient, May 2015
All excellent!
SHC Patient, Apr 2015
My experience with Dr. Maron was the best I have had with a doctor at Stanford.
SHC Patient, Feb 2015
Very, very professional!
SHC Patient, Jan 2015
Good.
SHC Patient, Dec 2014
Dr. Maron was fantastic. Explained his findings and clearly had reviewed my medical history. Made me feel at ease.